HLT: HLT launches feasibility trial for Meridian TAVR

HLT said today that it launched a feasibility trial of its Meridian TAVR in a high-risk patient cohort. Maple Grove, Minn.-based HLT said the 20-patient Radiant study is a prospective, non-randomized, single-arm trial with an endpoint of all-cause mortality at 30 days. Follow-up is slated for 1, 5 and 12 months after implantation, and then annually to 5 [...]The post HLT launches feasibility trial for Meridian TAVR appeared first on MassDevice.